Spain's Oryzon Genomics' Q3 net loss widens on higher R&D costs

Overview

• Spain biopharma firm's Q3 net loss widened as R&D expenses increased

• Company advanced iadademstat and vafidemstat clinical programs with new study authorizations and Cdata

• Cash position fell to $21.7 mln at end-Q3 2026 from $40.4 mln a year earlier

Outlook

• Company aims to initiate ALICE-3 Phase III trial in first-line AML in 2027

• Oryzon expects EVOLUTION Phase IIb schizophrenia trial enrollment to complete in spring 2027

• Company plans to request FDA Type C meeting for PORTICO-2 Phase III BPD trial by early 2027

Result Drivers

• R&D SPENDING - Co said higher research and development expenses reflected ongoing and expanded clinical trials for iadademstat and vafidemstat

• CLINICAL TRIAL PROGRESS - Co highlighted continued patient enrollment and new study authorizations for iadademstat and vafidemstat programs

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Oryzon Genomics SA is €6.00, about 152.3% above its November 9 closing price of €2.38

Reuters Recommended Reads

• Nov 9 - Biopharma Almirall 9M sales rise on European dermatology growth

• Nov 9 - Ionis Pharmaceuticals Q3 revenue rises 55%

• Nov 9 - Zura Bio's skin disease drug fails mid-stage trial

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)